During the recent session, Aurinia Pharmaceuticals Inc (NASDAQ:AUPH)’s traded shares were 1.71 million, with the beta value of the company hitting 1.23. At the last check today, the stock’s price was $8.93, reflecting an intraday gain of 6.47% or $0.54. The 52-week high for the AUPH share is $10.67, that puts it down -19.48 from that peak though still a striking 41.77% gain since the share price plummeted to a 52-week low of $5.20. The company’s market capitalization is $1.21B, and the average intraday trading volume over the past 10 days was 2.41 million shares, and the average trade volume was 1.36 million shares over the past three months.
Aurinia Pharmaceuticals Inc (AUPH) received a consensus recommendation of Buy from analysts. That translates to a mean rating of 1.50. AUPH has a Sell rating from 0 analyst(s) out of 3 analysts who have looked at this stock. 1 analyst(s) recommend to Hold the stock while 0 suggest Overweight, and 2 recommend a Buy rating for it.
Aurinia Pharmaceuticals Inc (NASDAQ:AUPH) trade information
Aurinia Pharmaceuticals Inc (AUPH) registered a 6.47% upside in the last session and has traded in the green over the past 5 sessions. The stock spiked 6.47% in intraday trading to $8.93, hitting a weekly high. The stock’s 5-day price performance is 19.27%, and it has moved by 9.74% in 30 days. Based on these gigs, the overall price performance for the year is -0.52%. The short interest in Aurinia Pharmaceuticals Inc (NASDAQ:AUPH) is 10.53 million shares and it means that shorts have 8.4 day(s) to cover.
The consensus price target of analysts on Wall Street is $12, which implies an increase of 25.58% to the stock’s current value. The extremes of the forecast give a target low and a target high price of $6 and $13 respectively. As a result, AUPH is trading at a discount of -45.58% off the target high and 32.81% off the low.
While earnings are projected to return 1365.00% in 2025.
AUPH Dividends
Aurinia Pharmaceuticals Inc is due to release its next quarterly earnings on 2025-May-12. However, it is important to remember that the dividend yield ratio is merely an indicator meant to only serve as guidance.
Aurinia Pharmaceuticals Inc (NASDAQ:AUPH)’s Major holders
Aurinia Pharmaceuticals Inc insiders own 9.07% of total outstanding shares while institutional holders control 47.22%, with the float percentage being 51.93%. ARMISTICE CAPITAL, LLC is the largest shareholder of the company, while 281.0 institutions own stock in it. As of 2024-06-30, the company held over 11.14 million shares (or 7.7696% of all shares), a total value of $63.59 million in shares.
The next largest institutional holding, with 9.27 million shares, is of BLACKROCK INC.’s that is approximately 6.4692% of outstanding shares. At the market price on 2024-06-30, these shares were valued at $52.94 million.
